VISTIN PHARMA ASA (VISTN.OL) Stock Fundamental Analysis
OSL:VISTN - NO0010734122 - Common Stock
23.4 NOK
+0.1 (+0.43%)
Overall VISTN gets a fundamental rating of 5 out of 10. We evaluated VISTN against 50 industry peers in the Pharmaceuticals industry. VISTN is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. VISTN has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
VISTN had positive earnings in the past year.
In the past year VISTN had a positive cash flow from operations.
In multiple years VISTN reported negative net income over the last 5 years.
In multiple years VISTN reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of VISTN (18.66%) is better than 96.00% of its industry peers.
Looking at the Return On Equity, with a value of 23.18%, VISTN is in the better half of the industry, outperforming 78.00% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 21.23%, VISTN belongs to the top of the industry, outperforming 88.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.66% | ||
| ROE | 23.18% | ||
| ROIC | 21.23% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VISTN has a better Profit Margin (17.44%) than 72.00% of its industry peers.
VISTN's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 21.55%, VISTN is in line with its industry, outperforming 58.00% of the companies in the same industry.
In the last couple of years the Operating Margin of VISTN has grown nicely.
With a Gross Margin value of 66.70%, VISTN perfoms like the industry average, outperforming 44.00% of the companies in the same industry.
In the last couple of years the Gross Margin of VISTN has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.55% | ||
| PM (TTM) | 17.44% | ||
| GM | 66.7% |
OM growth 3Y18.14%
OM growth 5Y21.91%
PM growth 3Y17.49%
PM growth 5Y-12.88%
GM growth 3Y-0.06%
GM growth 5Y7.35%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), VISTN is creating value.
VISTN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 10.39 indicates that VISTN is not in any danger for bankruptcy at the moment.
VISTN has a Altman-Z score of 10.39. This is amongst the best in the industry. VISTN outperforms 98.00% of its industry peers.
There is no outstanding debt for VISTN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 10.39 |
ROIC/WACC2.5
WACC8.48%
2.3 Liquidity
A Current Ratio of 2.69 indicates that VISTN has no problem at all paying its short term obligations.
VISTN has a Current ratio of 2.69. This is amongst the best in the industry. VISTN outperforms 88.00% of its industry peers.
A Quick Ratio of 1.47 indicates that VISTN should not have too much problems paying its short term obligations.
VISTN has a Quick ratio of 1.47. This is in the better half of the industry: VISTN outperforms 78.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.69 | ||
| Quick Ratio | 1.47 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 36.54% over the past year.
VISTN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.03% yearly.
VISTN shows a small growth in Revenue. In the last year, the Revenue has grown by 0.44%.
VISTN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.56% yearly.
EPS 1Y (TTM)36.54%
EPS 3Y36.14%
EPS 5Y-1.03%
EPS Q2Q%183.32%
Revenue 1Y (TTM)0.44%
Revenue growth 3Y15.87%
Revenue growth 5Y13.56%
Sales Q2Q%10.74%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
VISTN is valuated correctly with a Price/Earnings ratio of 13.53.
Based on the Price/Earnings ratio, VISTN is valued a bit cheaper than the industry average as 68.00% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.02, VISTN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.53 | ||
| Fwd PE | N/A |
4.2 Price Multiples
VISTN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. VISTN is cheaper than 72.00% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of VISTN indicates a rather cheap valuation: VISTN is cheaper than 84.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.03 | ||
| EV/EBITDA | 8.94 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
VISTN has a Yearly Dividend Yield of 5.32%, which is a nice return.
Compared to an average industry Dividend Yield of 3.06, VISTN pays a better dividend. On top of this VISTN pays more dividend than 92.00% of the companies listed in the same industry.
VISTN's Dividend Yield is rather good when compared to the S&P500 average which is at 2.45.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.32% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
57.73% of the earnings are spent on dividend by VISTN. This is a bit on the high side, but may be sustainable.
DP57.73%
EPS Next 2YN/A
EPS Next 3YN/A
OSL:VISTN (9/8/2025, 7:00:00 PM)
23.4
+0.1 (+0.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners12.54%
Inst Owner ChangeN/A
Ins Owners4.59%
Ins Owner ChangeN/A
Market Cap1.04B
Analysts40
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 5.32% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP57.73%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.53 | ||
| Fwd PE | N/A | ||
| P/S | 2.36 | ||
| P/FCF | 13.03 | ||
| P/OCF | 10.1 | ||
| P/B | 3.13 | ||
| P/tB | 3.13 | ||
| EV/EBITDA | 8.94 |
EPS(TTM)1.73
EY7.39%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)1.8
FCFY7.68%
OCF(TTM)2.32
OCFY9.9%
SpS9.93
BVpS7.47
TBVpS7.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.66% | ||
| ROE | 23.18% | ||
| ROCE | 27.23% | ||
| ROIC | 21.23% | ||
| ROICexc | 22.03% | ||
| ROICexgc | 22.03% | ||
| OM | 21.55% | ||
| PM (TTM) | 17.44% | ||
| GM | 66.7% | ||
| FCFM | 18.09% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y18.14%
OM growth 5Y21.91%
PM growth 3Y17.49%
PM growth 5Y-12.88%
GM growth 3Y-0.06%
GM growth 5Y7.35%
F-Score7
Asset Turnover1.07
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 120.19% | ||
| Cap/Sales | 5.25% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 90.04% | ||
| Profit Quality | 103.7% | ||
| Current Ratio | 2.69 | ||
| Quick Ratio | 1.47 | ||
| Altman-Z | 10.39 |
F-Score7
WACC8.48%
ROIC/WACC2.5
Cap/Depr(3y)280.38%
Cap/Depr(5y)338.81%
Cap/Sales(3y)11.99%
Cap/Sales(5y)13.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.54%
EPS 3Y36.14%
EPS 5Y-1.03%
EPS Q2Q%183.32%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)0.44%
Revenue growth 3Y15.87%
Revenue growth 5Y13.56%
Sales Q2Q%10.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y27.5%
EBIT growth 3Y36.89%
EBIT growth 5Y38.44%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y374.74%
FCF growth 3YN/A
FCF growth 5Y158.58%
OCF growth 1Y502.58%
OCF growth 3Y99.03%
OCF growth 5Y41.62%